Castle Biosciences, Inc. (CSTL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Take the Zacks Approach to Beat the Markets: Castle Biosciences, Hamilton Insurance & Monster Beverage in Focus
Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why 'Trend' Investors Would Love Betting on Castle Biosciences (CSTL)
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable
Castle Biosciences (CSTL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
5 Stocks With Recent Price Strength Amid Wall Street Volatility
CSTL, IDN, PANL, FSRL and PRM are showing sharp price strength amid renewed Wall Street volatility.
Forget the Fed, Bet on These 4 Stocks With Increasing Cash Flows
Four rising cash-flow stocks, including PRM, TILE, CSTL and GLDD, stand out with upgraded earnings estimates and strong VGM scores.
Recent Price Trend in Castle Biosciences (CSTL) is Your Friend, Here's Why
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript
Castle Biosciences, Inc. ( CSTL ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Camilla Zuckero - Vice President of Investor Relations & Corporate Affairs Derek Maetzold - Founder, CEO, President & Director Frank Stokes - CFO & Treasurer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Thomas Peterson - Robert W. Baird & Co. Incorporated, Research Division Mason Carrico - Stephens Inc., Research Division Vidyun Bais - BTIG, LLC, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Presentation Operator Good afternoon, and welcome to Castle Biosciences' Third Quarter 2025 Conference Call.
What Makes Castle Biosciences (CSTL) a New Strong Buy Stock
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations & Corporate Affairs Derek J. Maetzold - Founder, CEO, President & Director Frank Stokes - CFO & Treasurer Conference Call Participants Catherine Walden Ramsey Schulte - Robert W.
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to earnings of $0.31 per share a year ago.
